Phibro Animal Health Corporation (NASDAQ:PAHC): Today, the Food and Drug Administration (FDA) provided notice in the Federal Register of its intention to hold a public hearing regarding Mecadox® (carbadox).
Pulled from Benzinga Pro data, Phibro Animal Health (NASDAQ:PAHC) showed a loss in earnings since Q3, totaling $19.16 million. Sales, on the other hand, increased by 4.06% to $220.30 million during Q4.
Companies Reporting Before The Bell
• Thomson Reuters (NYSE:TRI) is expected to report quarterly earnings at $0.48 per share on revenue of $1.86 billion.
Shares of Phibro Animal Health (NASDAQ:PAHC) fell 2.2% in after-market trading after the company reported Q4 results.
Quarterly Results
Earnings per share rose 88.24% year over year to $0.32, which beat the estimate of $0.31.
Phibro Animal Health (NASDAQ:PAHC) reported quarterly earnings of $0.42 per share which beat the analyst consensus estimate of $0.31 by 35.48 percent. This is a 147.06 percent increase over earnings of $0.17 per share
Companies Reporting Before The Bell
• Jiayin Gr (NASDAQ:JFIN) is projected to report quarterly earnings at $0.21 per share on revenue of $54.80 million.
Shares of Phibro Animal Health (NASDAQ:PAHC) moved lower by 10.41% in the past three months. Before we understand the importance of debt, let us look at how much debt Phibro Animal Health has.